<DOC>
	<DOCNO>NCT00005631</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining combination chemotherapy monoclonal antibody therapy may kill cancer cell . PURPOSE : Phase II trial study effectiveness rituximab combination chemotherapy treat patient relapse refractory large cell lymphoma .</brief_summary>
	<brief_title>Rituximab Combination Chemotherapy Treating Patients With Relapsed Refractory Large Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine complete response rate patient relapse refractory CD20-positive diffuse large cell , immunoblastic , anaplastic large cell lymphoma treat cytoreduction mobilization rituximab , ifosfamide , carboplatin , etoposide ( RICE ) . II . Assess ability regimen deplete stem cell harvest B-cells tumor cell patient . III . Assess efficacy regimen mobilize peripheral blood progenitor cell patient . IV . Assess safety toxicity regimen patient . OUTLINE : Cytoreduction mobilization : Patients receive ifosfamide IV 24 hour carboplatin IV day 4 etoposide IV 1 hour day 3-5 . Chemotherapy repeat every 2 week 3 course . Patients receive rituximab IV day -2 initiation chemotherapy day 1 course chemotherapy . Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily day 7-14 course chemotherapy . Patients complete partial response completion course 3 continue receive G-CSF SC daily peripheral blood stem cell ( PBSC ) harvest . When blood count recover , PBSC harvest select CD34+ cell . If sufficient number CD34+ cell obtain , patient undergo bone marrow harvest . PROJECTED ACCRUAL : A total 36 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove nonHodgkin 's lymphoma first relapse refractory primary therapy Eligible type : Diffuse large cell Immunoblastic Anaplastic large cell Eligible autologous peripheral blood stem cell transplantation CD20positive disease Measurable disease No brain parenchyma involvement PATIENT CHARACTERISTICS : Age : 18 72 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,000/mm3 Platelet count great 50,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL unless due Gilbert 's disease No chronic persistent hepatitis Hepatitis B surface antigen negative Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min No chronic renal insufficiency Cardiovascular : Normal baseline cardiac function Ejection fraction least 50 % echocardiogram MUGA scan No myocardial infarction within past 6 month No unstable angina No cardiac arrhythmias except chronic atrial fibrillation Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception HIV negative No malignancy within past 5 year except basal cell squamous cell skin cancer carcinoma situ cervix No uncontrolled infection PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Prior rituximab allow Chemotherapy : No prior carboplatin cisplatin Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
</DOC>